Acta paediatrica (Oslo, Norway : 1992) · 2026
Health Economic Evaluation of Varicella Vaccination Within the Swedish National Vaccination Programme for Children.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kasteng Frida, Tomba Gianpaolo Scalia, Ersson Annika, Wolff Ellen, Andersson Sören, Johansen Kari
Аннотация
AIM: To assess the cost-effectiveness of including varicella vaccination in the Swedish national vaccination programme for children together with the added impact of catch-up vaccination of susceptible older children.
METHODS: An epidemiological transmission model was used to assess the cost-effectiveness of a two-dose national varicella vaccination programme, with and without a catch-up strategy, compared to no varicella vaccination. Parameter estimates were based on scientific publications and data from Swedish national and regional registries.
RESULTS: A national varicella vaccination programme would result in health gains and cost-savings from a societal perspective. Cost-savings were primarily due to a reduction in caregiver productivity loss. From a health system perspective, the cost per quality-adjusted life-year gained was estimated at around SEK 200 000 (EUR 18 000), both with and without catch-up vaccination. At a negotiated vaccine price reduction to 30% of the current list price, the cost per quality-adjusted life-year gained would come down to SEK 5 000 (EUR 450).
CONCLUSION: Our analyses suggest that inclusion of varicella vaccination in the national vaccination programme for children would be a cost-saving strategy from a societal perspective, which together with a catch-up vaccination offer for susceptible older children would result in a fast decline of varicella in Sweden.
METHODS: An epidemiological transmission model was used to assess the cost-effectiveness of a two-dose national varicella vaccination programme, with and without a catch-up strategy, compared to no varicella vaccination. Parameter estimates were based on scientific publications and data from Swedish national and regional registries.
RESULTS: A national varicella vaccination programme would result in health gains and cost-savings from a societal perspective. Cost-savings were primarily due to a reduction in caregiver productivity loss. From a health system perspective, the cost per quality-adjusted life-year gained was estimated at around SEK 200 000 (EUR 18 000), both with and without catch-up vaccination. At a negotiated vaccine price reduction to 30% of the current list price, the cost per quality-adjusted life-year gained would come down to SEK 5 000 (EUR 450).
CONCLUSION: Our analyses suggest that inclusion of varicella vaccination in the national vaccination programme for children would be a cost-saving strategy from a societal perspective, which together with a catch-up vaccination offer for susceptible older children would result in a fast decline of varicella in Sweden.